Astellas is shifting its investment focus toward more established modalities and later-stage opportunities, its chief strategy officer said. Mitsubishi Tanabe Pharma is being sold to Bain Capital ...

Marci English, head of biopharma and ophthalmology development at Astellas Pharma, said the FDA's change of heart will "further [solidify] Izervay's status as a trusted choice for thousands of GA ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Astellas Pharma has agreed its largest-ever acquisition, buying US biotech Iveric Bio in a deal that continues to build its presence in the ophthalmology sector, The $40-per-share offer values ...

Barclays analyst Gena Wang maintained a Buy rating on Alnylam Pharma (ALNY – Research Report) today and set a price target of $329.00. The company’s shares closed yesterday at $264.89.

In a report released yesterday, Gavin Clark-Gartner from Evercore ISI maintained a Buy rating on Ascendis Pharma (ASND – Research Report), with a price target of $220.00. The company’s shares ...

DOC Pharma strengthens its offerings with the acquisition of the Geopharma nutraceuticals portfolio, and the closing of the previously announced acquisition of Muscoril® New brand identity ...

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Sanofi S.A. Part Cert 0.02% €8.03M ...

Natco Pharma Ltd., incorporated in the year 1981, is a Mid Cap company (having a market cap of Rs 14,561.63 Crore) operating in Pharmaceuticals sector. Natco Pharma Ltd. key Products/Revenue Segments ...